Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study

R. Kodgule, S. Kapoor, R. Pawar, N. Vanjare, K. Gaikwad, S. Salvi, B. Brashier (Pune, India)

Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders?
Session: New or old physiological parameters in chronic airway disorders?
Session type: Oral Presentation
Number: 3872
Disease area: Airway diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Kodgule, S. Kapoor, R. Pawar, N. Vanjare, K. Gaikwad, S. Salvi, B. Brashier (Pune, India). Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study. Eur Respir J 2010; 36: Suppl. 54, 3872

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006

Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017


Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012


A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics
Source: International Congress 2017 – Novel studies on bronchodilators and cough
Year: 2017



A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics.
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007

Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

A multicentre, double-blind, double-dummy, randomized, parallel group study to assess efficacy and safety of beclomethasone dipropionate and ease of handling of a breath operated aerosol inhaler in adults with reversible airways obstruction
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008


The effect of montelukast added to steroid on airway function as compared with steroid alone and placebo: a single blind, controlled study in acute asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 263s
Year: 2001

Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Montelukast and steroid effects on airway function compared with steroid alone and placebo: a single blind, controlled study in asthmatic school children
Source: Eur Respir J 2003; 22: Suppl. 45, 132s
Year: 2003

Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


The TRIFLOW study; A randomised, cross-over study evaluating the effects of inhaled beclometasone/formoterol/glycopyrronium (BDP/F/G) on hyperinflation in COPD
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020